RNS Number : 6222E
BioVentix PLC
11 April 2025
Bioventix plc
("Bioventix" or the "Company")
Option Exercise, Director/PDMR Shareholding, and Total Voting Rights
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, was notified on 10 April 2025 that 5,204 options were exercised over its ordinary shares of 5 pence each ("Ordinary Shares") by Peter Harrison, Chief Executive Officer, at a price of 1,350 pence per Ordinary Share.
Following this transaction, Mr Harrison's holding in the Company is as detailed below:
Director
Number of options exercised
Number of options held post exercise
Number of Ordinary Shares post-exercise held
Resulting interest in fully diluted share capital %
Peter Harrison
5,204
19,811
302,292
5.79%
Application will be made for 5,204 new Ordinary Shares to be admitted to trading on AIM. Admission is expected to become effective on 16 April 2025. Following Admission, the Company will have 5,224,860 Ordinary Shares in issue. All Ordinary Shares shall have equal voting rights and none of the Ordinary Shares are held in treasury. The total number of voting rights in the Company immediately following Admission will therefore be 5,224,860.
For further information please contact:
Bioventix plc
Tel: 01252 728 001
Peter Harrison
Chief Executive Officer
Bruce Hiscock
Chief Financial Officer
Cavendish Capital Markets Limited
Tel: 020 7220 0500
Geoff Nash / Elysia Bough
Corporate Finance
Nigel Birks / Harriet Ward
ECM
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name of PDMR
Peter Harrison
2
Reason for notification
a.
Position/Status
Chief Executive Officer
b.
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
Bioventix plc
b.
LEI
213800225MHX7LZQY108
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument
Identification Code
Ordinary Shares of 5 pence each GB00B4QVDF07
b.
Nature of the transaction
Exercise of Options over Ordinary Shares
c.
Price(s) and volume(s)
No. of Shares
Price
Option exercise
5,204
1,350p
d.
Aggregated information - Aggregated Volume - Price
See above
e.
Date of the transaction
10 April 2025
f.
Place of the transaction
London Stock Exchange, AIM Market (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
IOEPKDBPDBKKQQD
